PharmiWeb.com - Global Pharma News & Resources
10-Dec-2019

Low dosage Hydrate Inhibitors Market estimated to Exhibit 8.0% CAGR through 2028

VALLEY COTTAGE, N.Y. – Global consumption of low dosage inhibitors is likely to increase at a robust pace over the course of forthcoming years. Future Market Insights (FMI) recently published a new research study titled – ‘Low Dosage Hydrate Inhibitors MarketGlobal Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028′. The report has projected the global low dosage hydrate inhibitors market for an impressive 8% CAGR between 2018 and 2028.

Application of low dosage inhibitors will be particularly high in the offshore terrain segment, according to FMI’s analysis. Estimated to achieve a massive incremental opportunity through 2028, more than 90% of overall consumption of low dosage hydrate inhibitors is expected to be registered by offshore terrain.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1298

Anti-agglomerate Inhibitors Hold Potential to Rise above Kinetic Hydrate Inhibitors

A majority of leading manufacturers have been accelerating the shift from the conventional thermodynamic inhibitors to low dosage hydrate inhibitors in an effort to achieve significant savings in terms of maintenance costs. Increasing acceptance of low dosage hydrate inhibitors will be further strengthened by cost benefit related to flow assurance and flow maintenance, storage, logistics, and pumping among others.

In addition, the BOD (biological oxygen demand) and COD (chemical oxygen demand) associated with low dosage hydrate inhibitors is significantly lesser than that with thermodynamic inhibitors. According to FMI’s study, superior sustainability quotient will continue to place low dosage hydrate inhibitors superior to thermodynamic inhibitors. In line with the increasing quest of sustainability, anti-agglomerate type of low dosage hydrate inhibitors, which are more degradable than kinetic hydrate inhibitors, will remain the most preferred compound in the global low dosage hydrate inhibitors market.

Preview Analysis Global Low dosage Hydrate Inhibitors Market Segmentation by Product Type (Anti-Agglomerate (AA) inhibitors, Kinetic Hydrate Inhibitors (KHI)); by Terrain Type (Onshore, Offshore): https://www.futuremarketinsights.com/reports/low-dosage-hydrate-inhibitors-market

China to Remain Dominant Producer & Consumer of Low Dosage Hydrate Inhibitors

China is expected to lead the overall low dosage hydrate inhibitors’ consumption, retaining the title of the largest producer and consumer of low dosage hydrate inhibitors, globally. North America accounted for more than 16% of the total revenues attained by global low dosage hydrate inhibitors in 2018. The report envisages that North America will remain among the most important markets for low dosage hydrate inhibitors throughout the period of study. Furthermore, this growth is primarily attributed to the region’s primacy in offshore gas production activities.

Although the report reaffirms supremacy of China and North America in the low dosage hydrate inhibitors landscape, the flourishing manufacturing scene in fast-developing regional pockets such as East Asia, MEA, and Latin America prompt at the speeding revenue growth of low dosage hydrate inhibitors.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1298

Consistently growing demand for low dosage hydrate inhibitors from emerging markets such as India and ASEAN countries is expected to create ample opportunities for the manufacturers of low dosage hydrate inhibitors in coming years. New offshore natural gas exploration projects are further expected to boost the consumption levels of low dosage hydrate inhibitors in MEA, through 2028.

Vendor Insights: Global Low Dosage Hydrate Inhibitors Market

The report has covered detailed strategic profiles of some of the top companies operating in the global low dosage hydrate inhibitors market, such as BASF SE, Schlumberger Limited, Arkema Group, Baker Hughes Incorporated (BGHE), Clariant AG, Ecolab Inc., Evonik Industries AG, Force Chem Technologies LLC, Halliburton Co., and Gas Hydrate LLC, among others.

Buy Low dosage Hydrate Inhibitors Market Research Report @ https://www.futuremarketinsights.com/checkout/1298

More from FMI’s Chemicals & Materials Market Insights Intelligence:

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

Mr. Abhishek Budholiya
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremarketinsights.com
FMI Blog: http://www.fmiblog.com/
Website: https:www.futuremarketinsights.com

Editor Details

Last Updated: 10-Dec-2019